DalCor Pharmaceuticals Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$6.96M
- Investors
-
5
DalCor Pharmaceuticals General Information
Description
Developer of medicinal drugs intended to facilitate the efficient treatment of cardiovascular diseases. The company focuses on the development of dalcetrapib, a therapeutic targeting patients with a specific genotype to reduce fatal and non-fatal myocardial infarction, enabling healthcare providers to offer personalized treatment options for post-acute coronary syndrome patients.
Contact Information
Website
www.dalcorpharma.comCorporate Office
- 2001 Boulevard Robert Bourassa
- Suite 1700
- Montreal, Quebec H3A 2A6
- Canada
Corporate Office
- 2001 Boulevard Robert Bourassa
- Suite 1700
- Montreal, Quebec H3A 2A6
- Canada
DalCor Pharmaceuticals Timeline
DalCor Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC | 28-Aug-2026 | $6.96M | Completed | Clinical Trials - Phase 3 | ||
| 5. Secondary Transaction - Private | 01-May-2026 | Completed | Clinical Trials - Phase 3 | |||
| 4. Later Stage VC (Series D) | 13-Sep-2023 | Completed | Clinical Trials - Phase 3 | |||
| 3. Later Stage VC | 14-Sep-2020 | Completed | Clinical Trials - Phase 3 | |||
| 2. Early Stage VC (Series B) | 13-May-2016 | $123M | $173M | Completed | Clinical Trials - Phase 3 | |
| 1. Early Stage VC (Series A) | 01-Jan-2015 | $50M | $50M | Completed | Startup |
DalCor Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| B Preferred | ||||||||
| A Preferred |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
DalCor Pharmaceuticals Comparisons
Industry
Financing
Details
DalCor Pharmaceuticals Competitors (86)
One of DalCor Pharmaceuticals’s 86 competitors is InCarda Therapeutics, a Venture Capital-Backed company based in West Jordan, UT.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| InCarda Therapeutics | Venture Capital-Backed | West Jordan, UT | ||||
| Cardurion | Venture Capital-Backed | Burlington, MA | ||||
| Renova Therapeutics | Venture Capital-Backed | Carlsbad, CA | ||||
| Aronora | Venture Capital-Backed | Portland, OR | ||||
| Amylyx Pharmaceuticals | Formerly VC-backed | Cambridge, MA |
DalCor Pharmaceuticals Signals
DalCor Pharmaceuticals Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Andes Growth | Family Office | Minority | ||
| Fonds de Developpement Économique | Venture Capital | Minority | ||
| TB Pharma | Venture Capital | Minority | ||
| CTI Life Sciences Fund | Venture Capital | Minority | ||
| Fonds de solidarite FTQ | PE/Buyout | Minority |
DalCor Pharmaceuticals FAQs
-
When was DalCor Pharmaceuticals founded?
DalCor Pharmaceuticals was founded in 2015.
-
Where is DalCor Pharmaceuticals headquartered?
DalCor Pharmaceuticals is headquartered in Montreal, Canada.
-
What is the size of DalCor Pharmaceuticals?
DalCor Pharmaceuticals has 7 total employees.
-
What industry is DalCor Pharmaceuticals in?
DalCor Pharmaceuticals’s primary industry is Drug Discovery.
-
Is DalCor Pharmaceuticals a private or public company?
DalCor Pharmaceuticals is a Private company.
-
What is DalCor Pharmaceuticals’s current revenue?
The current revenue for DalCor Pharmaceuticals is .
-
How much funding has DalCor Pharmaceuticals raised over time?
DalCor Pharmaceuticals has raised $315M.
-
Who are DalCor Pharmaceuticals’s investors?
Andes Growth, Fonds de Developpement Économique, TB Pharma, CTI Life Sciences Fund, and Fonds de solidarite FTQ have invested in DalCor Pharmaceuticals.
-
Who are DalCor Pharmaceuticals’s competitors?
InCarda Therapeutics, Cardurion, Renova Therapeutics, Aronora, and Amylyx Pharmaceuticals are some of the 86 competitors of DalCor Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process